Duopharma Biotech
Duopharma Biotech Berhad, a leading player in the pharmaceutical industry, is headquartered in Malaysia (MY) and operates extensively across Southeast Asia. Founded in 1970, the company has established itself as a key provider of generic and innovative medicines, focusing on areas such as oncology, cardiology, and anti-infectives. With a commitment to quality and affordability, Duopharma Biotech offers a diverse range of products, including prescription medications and over-the-counter solutions, distinguished by their rigorous adherence to international standards. The company has achieved significant milestones, including the introduction of Malaysia's first biosimilar product, solidifying its market position as a pioneer in biopharmaceuticals. Recognised for its contributions to healthcare, Duopharma Biotech continues to innovate, ensuring access to essential medicines while maintaining a strong commitment to sustainability and community health initiatives.
DitchCarbon Score
How does Duopharma Biotech's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Duopharma Biotech's score of 36 is higher than 69% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Duopharma Biotech's reported carbon emissions
In 2023, Duopharma Biotech reported total carbon emissions of approximately 44,000,000 kg CO2e, comprising 1,477,700 kg CO2e from Scope 1, 38,141,900 kg CO2e from Scope 2, and 4,085,800 kg CO2e from Scope 3 emissions. This represents a slight increase in Scope 1 emissions compared to 2022, where they were about 1,288,990 kg CO2e, while Scope 2 emissions remained relatively stable at approximately 38,062,900 kg CO2e. Scope 3 emissions saw a significant rise from about 672,600 kg CO2e in 2022 to the current figure. Duopharma Biotech has not disclosed specific reduction targets or initiatives as part of their climate commitments. However, they have consistently reported their emissions across all three scopes, indicating a commitment to transparency in their environmental impact. The company continues to monitor and disclose its greenhouse gas emissions, aligning with industry standards for sustainability reporting.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 30,665,150 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 1,287,990 | 0,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | 0,000,000 | 000,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Duopharma Biotech is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
